Indian maker of veterinary & human APIs, intermediates and finished dosage forms, market leader in veterinary APIs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 96 | 151 | 200 | 219 | 260 | 279 | 297 | 326 |
| Borrowings | 28 | 16 | 30 | 32 | 34 | 77 | 88 | 108 |
| Other Liabilities | 26 | 36 | 44 | 32 | 59 | 74 | 96 | 108 |
| Total Liabilities | 154 | 207 | 277 | 287 | 356 | 433 | 484 | 546 |
| AssetsFixed Assets | 68 | 64 | 89 | 88 | 86 | 143 | 170 | 164 |
| CWIP | 0 | 12 | 6 | 26 | 46 | 50 | 35 | 95 |
| Investments | 11 | 29 | 29 | 39 | 54 | 60 | 49 | 39 |
| Other Assets | 75 | 102 | 153 | 133 | 171 | 181 | 230 | 247 |
| Total Assets | 154 | 207 | 277 | 287 | 356 | 433 | 484 | 546 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 9 | 20 | 27 | 14 | 35 | 20 | 36 | 43 |
| Cash from Investing | -10 | -20 | -25 | -14 | -27 | -27 | -35 | -71 |
| Cash from Financing | 0 | -1 | -1 | -1 | -1 | -1 | -1 | 30 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -6 | 6 | 10 | -15 | 5 | -8 | -38 | -43 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (34.3×) and current (39.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 33.5% growth and a 34× exit, ₹3056 only delivers your return if you pay ₹5,352. The price is currently baking in 21% growth.
EPS grows 33.5%/yr for 5 years, then fades to 6% over 2, exits at 34×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 33.5% | 103.85 |
| FY28 | 33.5% | 138.64 |
| FY29 | 33.5% | 185.08 |
| FY30 | 33.5% | 247.09 |
| FY31 | 33.5% | 329.86 |
| FY32 | 19.8% ·fade | 395.01 |
| FY33 | 6.0% ·fade | 418.71 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.